



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

**Menlo Park, California, and Singapore, May 18, 2022** – ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. Wainwright Global Investment Conference. The conference will be held virtually and in-person from May 23 to 26, 2022.

The presentation will be available from Tuesday, May 24, 2022, at 7:00am ET for 90 days at this [link](#) and in the Investors section of ASLAN's [website](#).

ASLAN management will also be available for virtual one-on-one meetings throughout the conference. Please contact your representative at H.C. Wainwright to request a meeting.

#### **About ASLAN Pharmaceuticals**

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating *eblasakimab*, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and *farudodstat* (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit [www.aslanpharma.com](http://www.aslanpharma.com) or follow ASLAN on [LinkedIn](#).

**Ends**

#### **Media and IR contacts**

##### **Emma Thompson**

Spurwing Communications

Tel: +65 6206 7350

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

##### **Ashley R. Robinson**

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: [arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)